International Flavors & Fragrances
IFF · What the business does, what can go wrong, and how options sellers approach it
What it does
International Flavors & Fragrances makes the ingredients that give many everyday products their taste, smell and function. Its customers are other companies, not shoppers, so most people never see the IFF name on a label.
The business spans several areas: flavors for food and drinks, fragrances for perfume, personal care and household products, and ingredients made through biotechnology, such as enzymes and probiotics. The company's portfolio has changed over time through acquisitions and divestitures.
How it makes money
IFF sells ingredients and custom formulations to consumer goods, food and beverage, and other manufacturers. It often works closely with a customer to develop a flavor or scent for a specific product. Once that formula is built into a product, the customer tends to keep buying it, which can make revenue fairly repeatable.
Why investors own it
- Its ingredients go into everyday products that people buy in most economic conditions.
- Custom formulas and long customer relationships can make it harder for rivals to displace the company.
- Biotech ingredients offer a way to grow beyond traditional flavors and fragrances.
- The company has a dividend, though payouts are never guaranteed.
What can go wrong
- Raw material, energy and transport costs can squeeze margins if they can't be passed on to customers.
- Large customers have bargaining power and may push back on price.
- Debt taken on to fund acquisitions can limit flexibility if it stays high.
- Integrating acquisitions and selling businesses can be slow and disappointing.
- Weak consumer demand can lead customers to cut orders or destock.
What to watch
- Volume growth versus price increases
- Gross and operating margin trends
- Debt levels and progress on paying them down
- Portfolio changes, such as business sales
- Performance of the health and biosciences area
- Dividend decisions
- Commentary from large consumer goods customers
Options income angle
Options on IFF are generally available across several expirations, but trading is usually thinner than for mega-cap stocks. Bid-ask spreads can be wider, especially on strikes far from the current price, so liquidity can vary noticeably from one strike to another.
Implied volatility tends to rise around quarterly earnings, guidance changes and news about acquisitions or divestitures. A caution for anyone selling premium: a single earnings report or guidance cut can cause a sharp gap move that overwhelms the premium collected, particularly with cash-secured puts.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 27, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
IFF finished 2025 with a net loss, mostly because of a $1.153 billion goodwill impairment on its Food Ingredients business. Underlying sales and segment profits still grew, and the company used divestiture proceeds to pay down debt. The filing points to a sale process for Food Ingredients, antitrust investigations, and debt as the main things to follow.
How the business did
- Sales in 2025 of $10.890 billion decreased 5% from $11.484 billion in 2024, because divested businesses dropped out. On a comparable currency neutral basis (which removes exchange rates and sold businesses), sales increased 2%.
- The net loss attributable to shareholders was $361 million, or $1.41 per share. The $1.153 billion impairment was recorded after Food Ingredients was split off as its own segment. A $488 million gain on extinguishment of debt partly offset it.
- On a comparable currency neutral basis, Taste sales rose 4%, Health & Biosciences 3% and Scent 3%, while Food Ingredients fell 3% on weaker Protein Solutions volumes and the exit of low margin business. Pharma Solutions was divested in May 2025.
- Gross margin was 36.2% of sales, and interest expense fell to $229 million from $305 million on lower debt.
- Operating cash flow was $850 million versus $1.070 billion in 2024, on higher working capital and a larger incentive compensation payout. Divestitures brought in $2.269 billion of investing cash. The company paid $2.0 billion to buy back certain senior notes, paid dividends of $409 million and repurchased $38 million of stock.
Risks specific to this company
- Antitrust cases: The company faces antitrust investigations in a number of countries and class action lawsuits in the U.S. and Canada, and the filing says outcomes are uncertain. Fines or business restrictions are possible, and insurance may not cover the costs.
- Goodwill: Goodwill is the accounting value left from past acquisitions, and it can be written down if a business underperforms. Health & Biosciences passed its test with fair value above carrying value by only 9%. A 50 basis point rise in the discount rate would flip it to a 2% shortfall and an impairment charge.
- Debt: Total debt was approximately $5.994 billion. The revolving credit facility caps the ratio of net debt to credit adjusted EBITDA at 3.75x, and the ratio was 2.59 to 1.0. The filing says a credit rating downgrade could raise borrowing costs.
- Customers and suppliers: The 25 largest customers made up approximately 32% of sales, though no single customer reached 10%. For certain raw materials the company relies on a limited number of suppliers or regions, which leaves it exposed to tariffs and price swings.
- Overseas exposure: Approximately 72% of combined net sales in 2025 were to customers outside the U.S., so currency moves, sanctions and corruption rules in markets such as China, India, Brazil and Russia matter.
- Tax indemnity: If the 2021 N&B Transaction with DuPont loses its tax-free status because of certain actions, the company may have to indemnify DuPont. The filing calls this obligation potentially substantial.
What management is watching
- Portfolio: The filing describes an ongoing sale process for the Food Ingredients division and continued portfolio optimization. It warns that such deals are complex and may bring stranded costs.
- Spending: Management expects capital spending in 2026 of approximately 6% of sales, after re-prioritizing projects.
- Capital allocation: The stated aim is to keep investment grade ratings while investing, paying dividends, repurchasing shares and repaying debt. The share repurchase program began on October 1, 2025.
- Efficiency: Restructuring charges rose to $70 million on severance under the IFF Productivity Program, and management points to pricing and productivity gains as profit drivers.
- Measures: Management directs investors to comparable currency neutral results, adjusted operating EBITDA (consolidated margin of 19.2%) and the net debt to credit adjusted EBITDA ratio.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 3, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Sales rose 4% to $1.942 billion in the third quarter, with volume growth of 5% across all three segments. Reported results were hit by a $236 million loss on assets classified as held for sale, tied to a business the company plans to sell, which pushed continuing operations to a net loss of $127 million. The pending sale of the Food Ingredients business, expected to close in the second quarter of 2027, is also reshaping the company's cash and buyback plans.
How the business did
- Sales and gross profit: Third-quarter sales were $1.942 billion versus $1.869 billion a year earlier, or 5% on a comparable currency neutral basis (which strips out currency swings and divested businesses). Scent grew 6%, Taste 4% and Health & Biosciences 1%. Gross profit was $825 million (42.5% of sales) versus $799 million (42.8%), helped by $7 million of tariff refunds.
- Costs and charges: Selling and administrative expenses rose to $387 million from $348 million, mainly on additional regulatory costs of $28 million and higher incentive pay. A $23 million goodwill impairment also hit. Operating profit was $160 million versus $191 million. The effective tax rate was 5.2%, helped by the resolution of a Mexican tax matter.
- Year to date: Nine-month sales were $5.802 billion, down 1% as reported because of divestitures, but up 4% on a comparable currency neutral basis. Operating profit rose to $571 million from $511 million.
- Cash and capital return: Operating cash flow for nine months was $820 million versus $532 million, helped by lower working capital and a smaller incentive payout. The company spent $449 million on property, plant and equipment, paid dividends of $306 million and repurchased $584 million of stock. The net debt to credit adjusted EBITDA ratio, a covenant measure, was 2.75 to 1.0.
What management is watching
- Food Ingredients sale: Results for this business are reported as discontinued operations, meaning they are shown separately from ongoing results. Closing depends on customary conditions and regulatory approvals.
- Buybacks and debt: The Board authorized a $2.5 billion share repurchase program, including a $500 million accelerated repurchase (ASR) started in August. The rest is expected to be executed after the Food Ingredients sale closes, with completion by the end of 2027. A $1.0 billion term loan must be prepaid with that sale's net proceeds.
- Spending and measures: Capital spending in 2026 is expected to be approximately 5.5% of total company sales. Management points investors to comparable currency neutral sales and Segment Adjusted Operating EBITDA, which excludes items such as depreciation, restructuring and regulatory costs. Consolidated adjusted EBITDA margin for the quarter was 20.8% versus 20.5%.
Follow IFF in Kortex
The Kortex app shows IFF's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.